证券代码：002940 证券简称： 昂利康 浙江昂利康制药股份有限公司投资者关系活动记录表 编号： 2021-003 | --- | --- | --- | --- | --- | |--------------|----------------------------------|--------------------------------------------------------|--------------|------------------| | | | | | | | 投资者关系活 | 特定对象调研 □分析师会议 | | | | | 动类别 | □媒体采访 □业绩说明会 | | | | | | □新闻发布会 | □路演活动 | | | | | □现场参观 | | | | | | □其他（请文字说明其他活动内容） | | | | | 参与单位名称 | 银河证券李戈权 | | | | | 及人员姓名 | 个人投资者：宋文翔、徐峰 | | | | | 时间 | 2021 年 5 月 18 日上午 | 10:00 | | | | | 地点 公司三楼小会议室 | | | | | 上市公司接待 | ...

证券代码：002940 证券简称： 昂利康 浙江昂利康制药股份有限公司投资者关系活动记录表 编号：2021-002 | --- | --- | --- | |---------------|----------------------------------|--------------------------------------------------------| | | | | | 投资者关系活 | □特定对象调研 □分析师会议 | | | 动类别 | □媒体采访 | □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | 其他（电话会议） | | | 参与单位名称 | 东方证券承销保荐 | 王慧敏、王嘉乐 | | 及人员姓名 | 华泰资管胡兰王金成、上海铂绅董乐 | | | | 五矿证券梁良、张希斌、王洪阳 | | | 时间 | 2021 年 5 月 10 日下午 | 3:30 | | 地点 电话会议 | | | | 上市公司接待 | 副总经理、董事会秘书孙黎明 | | | 人员姓名 | 证券事务代表王燕红 | | | | 一、介绍公司 2020 | 年度的 ...

证券代码：002940 证券简称： 昂利康 编号： 2021-005 | --- | --- | --- | --- | |---------------|---------------------------------|---------------------------|------------------------| | | | | | | 投资者关系活 | | □特定对象调研 □分析师会议 | | | 动类别 | | □媒体采访 □业绩说明会 | | | | □新闻发布会 | □路演活动 | | | | □现场参观 | | | | | 其他（电话会议） | | | | 参与单位名称 | 光大证券研究所 | 林小伟、刘锡源 | | | 及人员姓名 | 上海楹联韩玮 | 浙商资管戴颖 | 群益投信郑羽庭 | | | 工银瑞信李善欣 | 西南证券陈进 | 淳厚基金陈文 | | | 中国再保险伊思杨 | 泰康资产王晓锋 | 国泰君安资管李子波 | | | 平安资产万淑珊 | 诺安基金李迪光 | 彤源投资薛凌云 | | | 富安达刘云鹏 | 天弘基金郭相博 | 民生加银肖志伟 | | | 富敦投资刘逸飞 ...

证券代码：002940 证券简称： 昂利康 浙江昂利康制药股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | |-------------------------|----------------------------------|----------------------------------------|--------------------------------------------------------| | | | | 编号： 2021-006 | | 投资者关系活动 | | 特定对象调研 □分析师会议 | | | 类别 | □媒体采访 | □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | | □现场参观 | | | | | □其他（请文字说明其他活动内容） | | | | 参与单位名称及 人员姓名 | 个人投资者：郑圣 | | | | 时间 | 2021 年 9 月 24 日上午 | 10 ： 00 | | | 地点 | 公司三楼小会议室 | | | | 上市公司接待人 | 证券事务代表王燕红 | | | | 员姓名 | 证券事 ...

1 证券代码：002940 证券简称： 昂利康 浙江昂利康制药股份有限公司投资者关系活动记录表 编号：2022-003 | --- | --- | --- | |----------------------------|--------------------------------|-----------------------------------------------------| | | | | | | | 特定对象调研 □分析师会议 | | 投 资 者关 系活动 | | □媒体采访 □业绩说明会 | | 类别 | | □新闻发布会 □路演活动 | | | □现场参观 | | | | 其他（电话） | | | | 中金 刘锡源，深国投 | - 尚雅 1 期 成佩剑 | | | | TEMASEK FULLERTON ALPHA PTE LTD SunTony | | | | 长城财富保险资产管理股份有限公司 胡纪元 | | | 中国通用技术 ( 集团 ) | 控股有限责任公司 程偲 | | | | 瀚伦投资大中华直通车私募投资基金 任靖 | | | | 上海勤辰私募基金管理合伙企业（有限合伙） 崔 ...

证券代码：002940 证券简称： 昂利康 浙江昂利康制药股份有限公司投资者关系活动记录表 编号：2022-002 | --- | --- | --- | --- | |-------------------------|---------------------------------------|--------------------------------------------------------|-------| | | | 特定对象调研 □分析师会议 | | | | □媒体采访 | □业绩说明会 | | | 投资者关系活 | □新闻发布会 □路演活动 | | | | 动类别 | □现场参观 | | | | | 其他（电话） | | | | | | 东吴证券研究所朱国广、徐梓煜、乔波耀、李倩 | | | | Pinpoint 卢聪， TKAMC | 刘勍，东方证券资管江琦 | | | | | 国海资管吴正明，国泰基金黄卓，泓澄投资殷萌 | | | | | 竑观投资朱戈宇，华夏财富程海泳，嘉实基金程佳、孙晓晖 | | | | | 建信郑丁源，江海自营罗萍，金元证券黄斌， | | | | | 景泰 ...

Financial Performance - The company's revenue for Q3 2022 was ¥359,329,021.98, representing a 1.75% increase year-over-year, while the year-to-date revenue reached ¥1,063,113,569.06, up 7.72% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2022 was ¥29,171,223.85, a significant increase of 203.43% year-over-year, with a year-to-date net profit of ¥108,275,724.51, reflecting a 44.00% increase[4] - The basic earnings per share for Q3 2022 was ¥0.31, marking a 210.00% increase compared to the same period last year, while the diluted earnings per share also stood at ¥0.31[4] - Total operating revenue for the third quarter reached ¥1,063,113,569.06, an increase of 7.8% compared to ¥986,885,462.15 in the same period last year[25] - The net profit for the third quarter of 2022 was CNY 113,440,888, an increase of 23.5% compared to CNY 91,813,306 in the same period last year[26] - The operating profit for the quarter was CNY 125,537,781, up from CNY 118,904,972, reflecting a growth of 5.4%[26] - The total revenue from sales of goods and services reached CNY 1,304,612,965, compared to CNY 1,142,063,944 in the previous year, marking an increase of 14.2%[27] - Basic and diluted earnings per share for the quarter were both CNY 1.15, up from CNY 0.78 in the previous year, representing a growth of 47.4%[27] - The total comprehensive income attributable to the parent company was CNY 108,275,725, compared to CNY 75,194,012 in the same period last year, reflecting a growth of 43.9%[26] Assets and Liabilities - The company's total assets as of September 30, 2022, were ¥2,427,816,704.62, a 16.52% increase from the end of the previous year[4] - Current assets decreased to ¥1,284,732,436.21 from ¥1,375,955,724.32, indicating a reduction in liquidity[22] - Total liabilities rose to ¥851,494,145.14 from ¥608,642,637.36, indicating increased financial obligations[23] - The company's equity attributable to shareholders increased to ¥1,432,424,818.35 from ¥1,338,853,095.62, reflecting retained earnings growth[23] Cash Flow - The net cash flow from operating activities for the first nine months of 2022 was ¥213,947,191.32, a 37.19% increase year-over-year, driven by higher cash receipts from sales[9] - The cash flow from operating activities generated a net amount of CNY 213,947,191, which is an increase of 37.2% from CNY 155,946,945 in the same period last year[27] - The company's cash flow from financing activities for the first nine months of 2022 was ¥200,579,871.01, a notable change from a cash outflow of ¥130,561,802.81 in the previous year, primarily due to new bank loans[9] - The financing activities resulted in a net cash inflow of CNY 200,579,871, reversing the outflow of CNY 130,561,803 from the same period last year[29] - The cash and cash equivalents at the end of the period were CNY 603,970,655, down from CNY 733,663,744 at the end of the previous year[29] Investments - The company reported a 503.00% increase in long-term equity investments, totaling ¥546,571,677.93, due to increased investments in joint ventures[8] - The company’s net profit from investment activities for the first nine months of 2022 was ¥7,502,078.82, a significant improvement compared to a loss of ¥14,467,528.91 in the same period last year[9] - The company reported an investment income of ¥7,502,078.82, a recovery from a loss of ¥14,467,528.91 in the previous year[25] - The company has completed the acquisition of 15.74% of Keri Bio-Pharmaceutical Co., Ltd. for RMB 157.48 million[14] - The company plans to acquire an additional 38.22% of Keri Bio-Pharmaceutical Co., Ltd. for RMB 191.30 million, pending shareholder approval[16] - The company has engaged in a strategic investment in Guangdong Yiduoli Biotechnology Co., Ltd. for RMB 200 million[13] Shareholder Information - The total number of common shareholders at the end of the reporting period is 9,259[11] - The largest shareholder, Shenzhou Juntai Investment Co., Ltd., holds 35.44% of shares, totaling 34,000,000 shares, with 13,825,000 shares pledged[11] - The top ten shareholders collectively hold 60.30% of the company's shares, indicating a concentrated ownership structure[12] Research and Development - Research and development expenses for the first nine months of 2022 amounted to ¥66,481,632.41, an increase of 82.54% compared to the same period in 2021, indicating a significant investment in innovation[9] - Research and development expenses increased significantly to ¥66,481,632.41, compared to ¥36,419,433.88 in the previous year, reflecting a focus on innovation[25] Inventory and Accounts Payable - The company experienced a 141.59% increase in accounts payable, reaching ¥232,839,776.00, attributed to an increase in issued payables during the reporting period[8] - Inventory levels increased to ¥371,298,600.06, up from ¥299,602,396.21, suggesting a buildup of stock[22]

Financial Performance - The company's operating revenue for the first half of 2022 was ¥703,784,547.08, representing an increase of 11.05% compared to ¥633,728,939.83 in the same period last year[26]. - The net profit attributable to shareholders for the first half of 2022 was ¥79,104,500.66, a 20.62% increase from ¥65,580,207.38 in the previous year[26]. - The net cash flow from operating activities increased by 61.37% to ¥212,313,335.25, up from ¥131,571,852.44 in the same period last year[26]. - The total assets at the end of the reporting period were ¥2,356,716,745.93, reflecting a growth of 13.11% from ¥2,083,578,310.62 at the end of the previous year[26]. - The company’s basic earnings per share increased by 23.53% to ¥0.84, compared to ¥0.68 in the same period last year[26]. - The company's operating profit for the first half of 2022 was ¥93.83 million, up 6.66% from ¥87.88 million in the first half of 2021[190]. - The company achieved an investment income of ¥6.56 million, a recovery from a loss of ¥5.63 million in the first half of 2021[190]. - The tax expense for the first half of 2022 was ¥7.75 million, down 33.06% from ¥11.59 million in the previous year[190]. Research and Development - The company is focused on enhancing its research and development capabilities to drive innovation in its product offerings[5]. - Research and development expenses rose significantly by 73.14% to ¥39,657,679.88, reflecting the company's increased investment in R&D[56]. - The company has made significant progress in its R&D projects, with several key generic drugs either approved or in various stages of registration[48]. - Anglikang is investing 200 million yuan in R&D for new technologies aimed at enhancing product efficacy and safety[131]. - The company plans to launch three new products in the next quarter, targeting a market share increase of 10% in the respective segments[131]. Market Strategy and Expansion - The company is actively pursuing market expansion strategies and potential mergers and acquisitions to strengthen its market position[5]. - The pharmaceutical industry is expected to grow due to increasing demand driven by an aging population and high-end medical needs, despite regulatory pressures[34]. - The company is exploring market expansion opportunities in Southeast Asia, with a projected revenue increase of 20% from this region by the end of 2023[131]. - The company has initiated discussions for potential mergers and acquisitions to strengthen its market position, focusing on companies with complementary product lines[131]. - The company plans to expand its market presence by entering three new provinces in China by the end of 2022, aiming for a 20% increase in market share[133]. Risk Management - The company emphasizes the importance of risk factors including regulatory changes, rising production costs, and the impact of the ongoing pandemic on operations[5]. - The company has outlined potential risks related to talent retention and the loss of core technical personnel, which could impact future growth[5]. - The company faces ongoing risks of rising production costs and drug price reductions due to national policies, which may compress profit margins while providing opportunities for sales expansion[89]. - The company is monitoring the ongoing pandemic situation, which could adversely affect operations if outbreaks occur[95]. - The company is at risk of talent shortages and core technical personnel turnover, which could impact operational efficiency; it plans to enhance talent recruitment and internal training[93]. Environmental and Social Responsibility - The company has highlighted the importance of environmental policies and safety production measures in its operational strategy[5]. - The company has established wastewater treatment facilities with a capacity of 1000t/d at its headquarters and Jiangsu Yuexin, and 72t/d at Haixi Pharmaceutical, all operating normally[107]. - The company’s wastewater discharge meets the standards set by relevant environmental regulations, with ammonia nitrogen and total phosphorus controlled according to specific limits[108]. - The company actively participates in social welfare activities, donating 1 million to the Shenzhou Charity Association after the reporting period[121]. - The company emphasizes social responsibility, focusing on economic benefits while protecting stakeholders' rights, particularly employees and customers[115]. Corporate Governance - The company is committed to maintaining transparency and accuracy in its financial reporting, as stated by its management team[4]. - The company has a comprehensive governance structure in place to oversee its operations and ensure compliance with regulatory requirements[4]. - The company has established a comprehensive corporate governance structure to protect shareholder and creditor rights, ensuring transparency and fairness in information disclosure[116]. - The company prioritizes employee welfare, providing a supportive work environment and adhering to labor laws to protect employee rights[118]. Shareholder Commitments - The company has committed to not transferring or entrusting the management of its shares for 36 months following the listing of its stock[124]. - The company will notify the market in writing about any intention to reduce its holdings of shares, with a notice period of 3 trading days[124]. - The company has committed to strict compliance with regulations regarding shareholder reductions and will notify the company of any intended share reductions[126]. - The company has not reported any violations of these commitments as of the current date[126]. Financial Management - The company reported a government subsidy income of ¥3,717,386.51 during the reporting period, contributing positively to its financial performance[30]. - The company reported a significant decrease of 82.99% in notes receivable, down to ¥5,380,148.21, due to the maturity of accepted bills[63]. - The company has established a joint venture named Jianrui Pharmaceutical with Hunan Kairui Biological, which was registered in June 2022[144]. - The company has cumulatively obtained 23.48% of Keri Pharmaceutical through agreements and block trades as of the report signing date[159].

Financial Performance - The company's revenue for Q1 2022 was CNY 338,209,274.21, representing a 6.06% increase compared to CNY 318,879,719.41 in the same period last year[4] - Net profit attributable to shareholders was CNY 39,086,498.56, up 19.23% from CNY 32,782,577.42 year-over-year[4] - Basic earnings per share rose to CNY 0.41, a 20.59% increase from CNY 0.34 in the previous year[4] - Total operating revenue for Q1 2022 was CNY 338,209,274.21, an increase of 6.6% compared to CNY 318,879,719.41 in Q1 2021[27] - Net profit for Q1 2022 reached CNY 42,077,608.52, representing a 15.5% increase from CNY 36,576,577.16 in Q1 2021[28] - Earnings per share for Q1 2022 were CNY 0.41, compared to CNY 0.34 in Q1 2021, indicating a growth of 20.6%[29] Cash Flow - The net cash flow from operating activities increased by 70.74%, reaching CNY 89,918,248.97 compared to CNY 52,662,779.65 in Q1 2021[12] - Total cash inflow from operating activities amounted to ¥456,326,128.89, while cash outflow was ¥366,407,879.92, resulting in a net inflow of ¥89,918,248.97[32] - The net cash flow from investing activities was -¥201,224,708.39, a significant decline from -¥42,650,301.10 in the previous year[33] - Cash inflow from financing activities totaled ¥122,000,000.00, while cash outflow was ¥331,880.05, leading to a net cash inflow of ¥121,668,119.95[33] Assets and Liabilities - Total assets at the end of Q1 2022 were CNY 2,245,359,613.67, reflecting a 7.76% increase from CNY 2,083,578,310.62 at the end of the previous year[4] - Total liabilities increased to CNY 726,146,304.21 in Q1 2022 from CNY 608,642,637.36 in Q1 2021, representing a rise of 19.3%[25] - The company's total non-current assets reached CNY 896,002,288.39 in Q1 2022, up from CNY 707,622,586.30 in Q1 2021, indicating a growth of 26.7%[25] Investments - The company reported a significant increase in long-term equity investments by 216.76%, totaling CNY 287,112,626.94 due to increased investments in joint ventures[10] - The company experienced a 371.80% increase in cash flow from investing activities, resulting in a net outflow of CNY 201,224,708.39, primarily due to increased investments in joint ventures[12] - The company plans to acquire a 12.55% stake in Hunan New He New Biopharmaceutical Co., Ltd. for RMB 20,000,000[18] - The company has completed the acquisition of 23.48% of Hunan Keri Biopharmaceutical Co., Ltd. for RMB 15,747,690[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 10,264[13] - The largest shareholder, Shenzhou Juntai Investment Co., Ltd., held a 35.44% stake in the company[13] - The company repurchased a total of 2,060,000 shares, representing 2.15% of the total share capital, with a total transaction amount of RMB 63,330,916[16] Operational Expenses - Total operating costs for Q1 2022 were CNY 292,776,746.73, up from CNY 281,195,280.82 in the same period last year, reflecting a year-on-year increase of 4.6%[27] - The company reported a decrease in sales expenses to CNY 133,286,139.03 in Q1 2022 from CNY 144,055,029.38 in Q1 2021, a reduction of 7.5%[28] - Research and development expenses for Q1 2022 amounted to CNY 14,730,302.82, up from CNY 11,344,978.86 in Q1 2021, marking a 30.5% increase[28] Other Financial Activities - The company has applied for a bank loan of up to RMB 30,000,000, with RMB 19,000,000 already drawn down[17] - The company is in the process of planning a major asset restructuring through a share issuance[21] - The first phase of the employee stock ownership plan is under consideration and requires shareholder approval[20] - The company did not conduct an audit for the Q1 report, as indicated in the audit report[34]

Financial Performance - The company's operating revenue for 2021 was ¥1,380,377,636.93, representing a 7.04% increase compared to ¥1,289,647,101.26 in 2020[18]. - The net profit attributable to shareholders for 2021 was ¥119,844,202.86, a decrease of 26.80% from ¥163,719,116.52 in 2020[18]. - The net profit after deducting non-recurring gains and losses was ¥107,857,508.30, down 19.51% from ¥134,000,807.56 in 2020[18]. - The company's total assets at the end of 2021 were ¥2,083,578,310.62, an increase of 7.36% from ¥1,940,754,044.72 at the end of 2020[18]. - The basic earnings per share for 2021 was ¥1.27, a decline of 29.83% compared to ¥1.81 in 2020[18]. - The weighted average return on net assets decreased to 9.13% in 2021 from 16.11% in 2020, a drop of 6.98 percentage points[18]. - The net cash flow from operating activities for 2021 was ¥197,652,364.35, a slight decrease of 0.48% from ¥198,612,986.30 in 2020[18]. - The company reported a total of ¥11,986,694.56 in non-recurring gains for 2021, down from ¥29,718,308.96 in 2020[24]. Market Expansion and Product Development - The company is actively involved in new product development and has faced challenges with the consistency evaluation of major products[4]. - The company has expanded its market presence by acquiring a controlling stake in Haixi United Pharmaceutical Co., Ltd. in August 2021[12]. - The company is focusing on expanding its product line with new drugs, although future production and sales remain uncertain for many of these products[64][65]. - The company completed the registration of three new products, including compound α-keto acid tablets and sevoflurane raw materials[41]. - The company is actively expanding into new markets, including pet pharmaceuticals and medical aesthetics, through strategic partnerships and joint ventures[43]. Research and Development - The company is focused on enhancing its R&D capabilities to innovate and develop new drugs, particularly in the field of generic drugs[4]. - R&D investment has been increased to enhance project progress and attract high-end talent, focusing on differentiated competitive products in the pharmaceutical sector[41]. - The company has several new drug projects in progress, including the approval of Ticagrelor tablets and the completion of bioequivalence studies for various products[64][65]. - The number of R&D personnel increased by 22.89% to 102 in 2021 from 83 in 2020[66]. - The company plans to increase its R&D investment to enhance its core competitiveness and accelerate the development of new products, including the "HC008" project and the expansion of alpha-keto acid raw material production[108]. Risk Management - The company acknowledges various risks including rising production costs, regulatory changes, and the impact of the ongoing pandemic on operations[4]. - The company has highlighted the need for risk awareness among investors regarding potential unlisted risks[4]. - The company acknowledges the risks associated with new product development, including potential delays and failures, and plans to implement rigorous project management to mitigate these risks[117]. - The company is prepared to address the ongoing impacts of the pandemic on its operations, ensuring that production and business activities are organized effectively[119]. - The company is actively monitoring industry regulatory changes and will adapt its internal management to comply with new standards, aiming to maintain operational stability[109]. Governance and Compliance - The company emphasizes the protection of minority shareholders' rights and has conducted shareholder meetings in compliance with legal requirements, ensuring transparency and fairness[128]. - The board of directors operates with a clear division of responsibilities and has established four specialized committees to provide professional opinions for decision-making[129]. - The company adheres to strict information disclosure practices, complying with relevant laws and regulations to maintain transparency[130]. - The company has established a comprehensive internal control system to protect the rights of shareholders and creditors, ensuring fair and transparent communication[191]. - The company has identified no violations of national regulations or the China Securities Regulatory Commission's requirements during its governance self-inspection[177]. Environmental and Social Responsibility - The company has established wastewater treatment facilities with a design capacity of 1,000 tons per day at its headquarters and Jiangsu Yuexin, and 72 tons per day at Haixi Pharmaceutical, all operating normally[182]. - The company has implemented a robust environmental management system that meets pollution control requirements and ensures stable compliance with discharge standards[182]. - The company has achieved ISO14001 certification for its environmental management system, reflecting its commitment to environmental protection[194]. - The company has actively participated in social welfare activities, including donations of epidemic prevention materials and support for underprivileged families[195]. - The company has implemented a comprehensive review of its governance structure, financial operations, and compliance with regulatory requirements, leading to identified areas for improvement[177]. Shareholder and Financial Policies - The company plans to distribute a cash dividend of 3.00 RMB per 10 shares to all shareholders, based on a total of 93,886,819 shares[4]. - The company maintained a transparent and compliant cash dividend policy, ensuring the protection of minority shareholders' rights[169]. - The total cash dividend, including other methods, reached RMB 91,505,097.05 for the reporting period[169]. - The company has committed to not transferring or entrusting the management of its shares for 36 months from the date of stock listing, with a lock-up period extending for an additional 6 months if certain conditions are met[198]. - The company must notify the stock exchange of any intended share reductions 3 trading days in advance[200].